New hope for Tough-to-Treat lymphoma patients after chemo fails
NCT ID NCT01909934
Summary
This study tested whether the drug brentuximab vedotin could shrink tumors in adults with anaplastic large cell lymphoma that had returned or didn't respond to previous chemotherapy. Fifty participants received the drug through an IV every three weeks. Researchers measured how many people's cancer responded and how long those responses lasted.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ankara University Medical Faculty
Ankara, 06340, Turkey (Türkiye)
-
Birmingham Heartlands Hospital
Birmingham, West Midlands, B9 5SS, United Kingdom
-
Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria
Lisbon, 1649-035, Portugal
-
Centro Hospitalar do Porto, E.P.E. - Hospital de Santo Antonio
Porto, 4099-001, Portugal
-
Centrum Onkologii-Instytut im. M. Sklodowskiej Curie
Warsaw, 02-781, Poland
-
Clinical Hospital Centre Rijeka
Rijeka, 51000, Croatia
-
Clinical Hospital Centre Zagreb
Zagreb, 10000, Croatia
-
Clinical Hospital Dubrava
Zagreb, 10000, Croatia
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Debreceni Egyetem Klinikai Kozpont
Debrecen, 4032, Hungary
-
Dokuz Eylul University Faculty of Medicine
Izmir, 35340, Turkey (Türkiye)
-
Ege University Medical Faculty
Izmir, 35040, Turkey (Türkiye)
-
Erciyes University Medical Faculty
Kayseri, 38039, Turkey (Türkiye)
-
Fakultni nemocnice Brno
Brno, 625 00, Czechia
-
Fakultni nemocnice Kralovske Vinohrady
Prague, 100 34, Czechia
-
Fakultni nemocnice Olomouc
Olomouc, 779 00, Czechia
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, 39008, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
-
Hospital Universitario de Salamanca
Salamanca, 37007, Spain
-
Hospital de Braga
Braga, 4710-243, Portugal
-
ICO lHospitalet Hospital Duran i Reynals
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE
Porto, 4200-072, Portugal
-
Istanbul Bilim University Medical Fac.
Istanbul, 34200, Turkey (Türkiye)
-
Malopolskie Centrum Medyczne s.c.
Krakow, 30-510, Poland
-
Pamukkale Uni. Med. Fac.
Denizli, 20070, Turkey (Türkiye)
-
Pecsi Tudomanyegyetem
Pécs, 7624, Hungary
-
Policlinica de Diagnostic Rapid SA
Brasov, 500152, Romania
-
Royal Cornwall Hospital
Truro, Cornwall, TR1 3LJ, United Kingdom
-
SPZOZ MSW zWarminsko-MazurskimCen.Onko.wOlsztynie
Olsztyn, 10-228, Poland
-
Semmelweis Egyetem
Budapest, 1083, Hungary
-
Spitalul Clinic Colentina
Bucharest, 020125, Romania
-
Spitalul Clinic Coltea
Bucharest, 030171, Romania
-
Spitalul Clinic Judetean de Urgenta Targu Mures
Târgu Mureş, 540042, Romania
-
The Christie
Manchester, Greater Manchester, M20 4BX, United Kingdom
-
UZ Leuven
Leuven, 3000, Belgium
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
Uniwersyteckie Centrum Kliniczne
Gdansk, 80-952, Poland
-
Vseobecna fakultni nemocnice v Praze
Prague, 128 08, Czechia
-
ZNA Stuivenberg
Antwerp, 2060, Belgium
Conditions
Explore the condition pages connected to this study.